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Introduction
The 25th Annual San Antonio Breast Cancer Symposium
attracted nearly 5000 physicians and researchers in
breast oncology, as well as other health care professionals
and patient advocates with an interest in breast cancer.
This meeting has become a key forum for the presentation
and discussion of scientific, translational and clinical
aspects of breast cancer care. The present report will
focus on the preclinical and translational highlights of the
meeting. The clinical research presented at the meeting is
discussed in another report, also published in the present
issue of Breast Cancer Research [1].
The work presented, as ever, was diverse and stimulating.
Three plenary lectures were given addressing growth
factor signalling, cancer genomics and proteomics, while
two minisymposia were devoted to epithelial–stromal
interactions and cancer genetics: ‘BRAC1 and 2 and
beyond’. There were also general presentations of original
research, and a large number of posters covering other
topics of interest such as protein arrays and the develop-
ment of novel prognostic and predictive markers.
Growth factor pathways and signalling
Elucidation of the signal transduction cascade down-
stream from growth factors and receptor tyrosine kinases
has revealed several key proteins that promote cell prolif-
eration and cell survival. Interest in the field of signalling
continues to grow, and this year’s meeting was launched
by a lecture from Robert Nicholson (Tenovus Centre for
Cancer Research, Cardiff, UK). Nicholson focused on the
complex signalling pathways of the oestrogen receptor
(ER) and, in particular, the development of endocrine-
resistant disease. Inappropriate activation of growth
factors, such as epidermal growth factor (EGF), insulin-like
growth factor (IGF) and heregulins, and the subsequent
upregulation of downstream signalling cascades, results in
a sustained induction of cell proliferation and survival
mechanisms that ultimately override the antitumour effect
of endocrine treatments. Several growth factor-induced
protein kinases such as protein kinase B (AKT) and
mitogen-activated protein kinase (MAPK/ERK) can target
and phosphorylate key regulatory sites on the ER. There is
also evidence of a positive feedback loop as the phospho-
rylated ER is able to increase the levels of growth factors
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such as EGF, in an independent fashion. Robert Nichol-
son went on to demonstrate that it is possible to block the
EGF/HER-2/MAPK pathways in vitro, with novel agents
such as ZD 1839 (Iressa), and to consequently inhibit the
growth of anti-oestrogen-resistant cells.
These findings were supported by some data presented
by Jiang Shou (Bayer College of Medicine, Houston, TX,
USA), who showed that, in a xenograft model of breast
cancer, the combination of Iressa and tamoxifen results in
greater antitumour effect compared with either drug alone,
and that the combination can delay the development of
acquired endocrine resistance [2]. Studies in tumour
models of breast cancer to date indicate that increased
growth factor signalling clearly represents a mechanism
for the development of endocrine resistance. If we are to
design better treatments, then we must not consider ER
signalling in isolation from the rest of the complex biology
of cancer cells.
Proteomics in cancer prevention and
treatment
As the human genome project progresses, the next chal-
lenge facing biologists is to understand the functional sig-
nificance of the genes identified. The phenotype of a given
cell is ultimately determined by the composition and the
activation status of its proteins. The study of the proteome
and protein expression is a rapidly expanding area of
research that provides us with novel data on functional
cellular content, and thus complements genomic DNA and
gene expression analyses.
The plenary lecture by Emanuel Petricoin (Food and Drug
Administration, Bethesda, MD, USA) gave insight into how
emerging proteomic technology might, in the future, be
used as a clinical tool in the diagnosis of cancer. The
serum proteome consists of multiple proteins and pep-
tides that are too numerous to identify individually. It is
possible, however, to look at emerging patterns of pro-
teome expression using a novel informatic tool, which can
distinguish the malignant phenotype from benign condi-
tions. Proteins from blood samples bind to the surface of a
mass spectroscopy chip and patterns of protein expres-
sion can then be mined using an artificial intelligence-
based software package. The state of signalling pathways
in an individual patient’s tumour can be demonstrated
using these protein arrays and, hence, the most suscepti-
ble targets for treatment may be identified.
This technology has future clinical applications in a variety
of tumours including lung, prostate and ovarian carcinoma.
In breast cancer, one of the first applications would be as
an adjunct to mammography in detecting early disease. An
example of this was illustrated by LLL Wilson (Eastern Vir-
ginia Medical School, Norfolk, VA, USA), who described
the use of proteomics technology to create a simple test
for breast cancer detection [3]. A specific mass spectrom-
etry technique was used to generate protein profiles from
the sera of women with breast cancer and from controls.
Serum profiles were thereby identified that were consis-
tent with a diagnosis with breast cancer. Crossvalidation
studies demonstrated high levels of sensitivity and speci-
ficity. If validated in larger studies, techniques such as this
could prove to be powerful adjuncts to existing methods
of breast cancer detection.
The ultimate goal is to apply proteomic technology to the
treatment of cancer and to the development of patient-
tailored therapy.
Prognostic and predictive factors
The delivery of adjuvant systemic therapy inevitably
involves the overtreatment of some patients (who would
be cured by local therapy alone), and the undertreatment
of others. In his plenary lecture, Stephen Friend (Rosetta
Inpharmatics/Merck Research, Westpoint, PA, USA) out-
lined the need to identify molecular profiles that could
predict which patients have a high risk of relapse. Adju-
vant therapy could in this way be reserved for those most
likely to benefit, maximising therapeutic effects while min-
imising unnecessary toxicity. It may be possible not only to
identify profiles predicting relapse (prognostic profiles),
but also to predict which treatments are most likely to be
effective (predictive profiles). The expansion of molecular
oncology, and in particular the development of cDNA
microarrays, has made this a clinical reality.
Jonas Bergh (Karolinska Institute and Hospital, Stockholm,
Sweden) presented results of a microarray analysis of a
cohort of 186 patients treated for breast cancer between
1994 and 1996, and from whom stored frozen tissue was
available [4]. The RNA from the tissue was extracted and
examined using two different gene chips of 39,000 and
10,000 genes, respectively. By comparing the gene
expression profiles with outcome, a set of 100 genes were
identified that were thought to have the greatest prognos-
tic importance in this cohort. Twenty-one per cent of the
patients in this series had received adjuvant chemother-
apy, however, and it is therefore important to stratify for
treatment effects. In addition, the training profiles gener-
ated require further validation using independent data
sets. Nonetheless, gene expression profiling using cDNA
microarrays represents a major advance in estimating
prognosis and predicting responses to therapy.
Friend emphasised that molecular profiling should not be
viewed in isolation, but should be regarded as complimen-
tary to, and used in parallel with, existing pathological
parameters. When putative prognostic or predictive genes
are proposed by molecular profiling, it may be desirable to
compare gene expression with expression of downstream
proteins. The construction of tissue microarrays may111
enhance our ability to do this [5]. Tissue microarrays
consist of cores of tumour taken from multiple patients
and arranged on a single array. These cohorts of patients
can then be rapidly screened for proposed prognostic or
predictive markers using immunohistochemical tech-
niques. Because these arrays are constructed prospec-
tively, they represent an important biological resource.
Novel markers of interest not initially identified at the time
of trial design may be retrospectively investigated.
The importance of retrospective analysis of biological
markers was illustrated by an update of the National Sur-
gical Adjuvant Breast and Bowel Project (NSABP)
trial 24 given by Craig Allred (Baylor College of Medicine,
Houston, TX, USA) [6]. In this trial, 1804 women with
ductal carcinoma in situ (DCIS) treated by excision and
radiotherapy had been randomised to tamoxifen or
placebo. When first published in 1999, women in the
tamoxifen-treated group were found to have fewer breast
cancer-related deaths than those in the placebo group,
but the findings were not stratified for ER status [7]. In
this update, ER status was available for 676 patients
(450 analysed centrally and 226 analysed externally).
Tamoxifen reduced the risk of invasive breast cancer
recurrence in ER-positive patients (relative risk=0.41,
P=0.0002). There was also a reported benefit in ER-
negative patients, but this was not statistically significant
(relative risk=0.8, P=0.51). Allred pointed out that the
trend to benefit in ER-negative patients was only seen in
the externally tested samples where the rate of ER-nega-
tive tumours was higher. This raises the possibility of
false-negative reporting in the externally tested cases,
which would explain the apparent trend to benefit from
tamoxifen in ER-negative patients.
The potential clinical utility of predictive biological markers
was demonstrated in a study presented by Nadia Harbeck
and colleagues (Technical University, Munich, Germany)
concerning the invasion factors urokinase-type plasmino-
gen activator (uPA) and plasminogen activator inhibitor-1
(PAI-1) [8]. These factors are recognised as having prog-
nostic significance in breast cancer: patients with high
tumour levels of either factor have a significantly worse
prognosis than patients with low levels. The data pre-
sented, however, suggest that these factors may also have
a predictive impact on responses to adjuvant chemother-
apy and endocrine therapy. uPA and PAI-1 antigen levels
were measured by enzyme-linked immunoadsorbent assay
(ELISA) in 3424 primary tissue extracts, and were com-
pared with subsequent disease-free survival. As previously
shown, patients with high uPA/PAI-1 levels were found to
have a worse disease-free survival than those with low
levels. However, this study also demonstrated that high
levels of these factors predicted an enhanced benefit from
adjuvant chemotherapy in certain patient groups. In node-
negative patients who have low levels of uPA/PAI-1, the
overall risk of relapse is low and it may be possible to
avoid adjuvant systemic chemotherapy. Node-negative
patients with high uPA/PAI-1 levels, however, are at signif-
icant risk of relapse, and systemic treatment in these
cases is warranted. The elaboration of factors such as
uPA/PAI-1 considered in conjunction with established
pathological parameters will improve treatment decisions
in the adjuvant setting.
Genetics
A minisymposium on breast cancer genetics provided a
timely update on current understanding of breast cancer
susceptibility genes. Ashok Venkitaraman (University of
Cambridge, UK) reviewed the putative biological functions
of BRCA1 and BRCA2, focusing particularly on the chro-
mosomal instability that arises following gene mutations.
When DNA double-strand breaks occur, repair is either by
homologous recombination, which is error free, or by non-
homologous end joining, which is error prone. BRCA1-
deficient and BRCA2-deficient cells are not able to repair
by homologous recombination, and therefore have to rely
on error-prone nonhomologous end joining. This could
explain the spontaneous chromosomal instability of
BRCA-deficient cells, underpinning their mutability and
propensity for neoplastic transformation. Under normal cir-
cumstances, however, a cell with such chromosomal
instability would not be viable. It is therefore postulated
that further mutations, particularly in genes crucial to the
cell cycle checkpoints, must also be mutated to allow the
continued proliferation and survival of these defective
cells. One such gene is CHK2, and this was discussed
further in a complimentary presentation given by Daniel
Haber (Massachusetts General Hospital, Charlestown,
MA, USA).
The clinical impact of susceptibility genes must not be
underestimated. Judy Garber (Dana-Farber Cancer Insti-
tute, Boston, MA, USA) discussed the difficulties encoun-
tered when screening this patient group. The high rate of
interval breast cancers seen with mammography contin-
ues to cause concern, and Garber presented data from
some small studies suggesting that magnetic resonance
imaging may be the screening modality of choice. Data
published earlier in 2002 demonstrate that prophylactic
oopherectomy in carriers of BRCA1 or BRCA2 mutations
may reduce the risk of both ovarian and breast cancer with
hazard ratios of 0.04 and 0.47, respectively [9]. It was
finally emphasised that, while bilateral prophylactic mas-
tectomy may reduce the risk of breast cancer by approxi-
mately 90%, the risk reducing roles of tamoxifen and oral
contraceptives remain less well studied.
Conclusion
The 25th San Antonio Breast Cancer Symposium was the
largest meeting to date, and the range of scientific and
translational research covered was impressive. Continued
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advances in genetics, proteomics and cell signalling have
increased our understanding of the pathogenesis of
breast cancer and, in particular, the development of resis-
tant disease. With ever-advancing technology this knowl-
edge is readily translated into the clinical arena and, as
novel targets for breast cancer detection and treatment
are being identified, the concept of patient-tailored man-
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